If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cymbalta ® (duloxetine)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Cymbalta Summary of Product Characteristics (SmPC)
Cymbalta (duloxetine): Overdose
Cases of overdose with duloxetine have been reported, alone or in combination with other medicinal products.
Cases
of overdoses, alone or in combination with other medicinal products,
with duloxetine doses of 5400 mg were reported. Some fatalities have
occurred, primarily with mixed overdoses, but also with duloxetine
alone at a dose of approximately 1000 mg. Signs and symptoms of
overdose (duloxetine alone or in combination with other medicinal
products) included somnolence, coma, serotonin syndrome, seizures,
vomiting and tachycardia.
No
specific antidote is known for duloxetine but if serotonin syndrome
ensues, specific treatment (such as with cyproheptadine and/or
temperature control) may be considered. A free airway should be
established. Monitoring of cardiac and vital signs is recommended,
along with appropriate symptomatic and supportive measures. Gastric
lavage may be indicated if performed soon after ingestion or in
symptomatic patients. Activated charcoal may be useful in limiting
absorption.
Duloxetine
has a large volume of distribution and forced diuresis,
haemoperfusion, and exchange perfusion are unlikely to be beneficial.
REFERENCE
Cymbalta
[Summary of Product Characteristics]. Utrecht, The Netherlands: Eli
Lilly Nederland B.V.
Date of Last Review:December 07, 2018
Are you satisfied with this content?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com